Meeting
2014 ASCO Annual Meeting
BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).
Authors
Karl D. Lewis
University of Colorado Cancer Center, Aurora, CO
Karl D. Lewis , Michele Maio , Mario Mandalà , Betty J Nelson , Grant R. Goodman , Dirk Schadendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01667419
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9118^)
DOI
10.1200/jco.2014.32.15_suppl.tps9118
Abstract #
TPS9118^
Poster Bd #
314A
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
First Author: Hope S. Rugo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.
First Author: Zheng Wu
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.
First Author: Manan Shah